Nanoscope Therapeutics Announces Presentations at the American Academy of Ophthalmology Annual Meeting 2023
DALLAS, Oct. 30, 2023 /PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced presentations at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting and Eyecelerator @ AAO 2023 taking place in San Francisco, California. Details for the presentations are as follows:
Eycelerator @ AAO 2023
During his presentation, Dr. Barone will showcase our Multi-Characteristic Opsin platform and its potential to restore vision based on recent clinical data in patients with advanced retinal degenerative diseases.
American Academy of Ophthalmology (AAO) 2023 Annual Meeting
During his presentation, Dr. Tsang will discuss end-of-study data from our Phase 2 STARLIGHT trial of MCO-010 therapy in patients with severe vision loss due to Stargardt disease.
About Nanoscope Therapeutics Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nanoscope-therapeutics-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2023-301970848.html
SOURCE Nanoscope Therapeutics